CN104470899B - 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 - Google Patents

作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 Download PDF

Info

Publication number
CN104470899B
CN104470899B CN201380023358.XA CN201380023358A CN104470899B CN 104470899 B CN104470899 B CN 104470899B CN 201380023358 A CN201380023358 A CN 201380023358A CN 104470899 B CN104470899 B CN 104470899B
Authority
CN
China
Prior art keywords
hydroxy
amino
isoquinoline
carbonyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380023358.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104470899A (zh
Inventor
何文彬
赵鸿达
邓少江
丹尼·吴
李·R·莱特
吴敏
周晓提
迈克尔·P·阿兰德
李·A·弗利平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen China Medical Technology Development Co Ltd
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of CN104470899A publication Critical patent/CN104470899A/zh
Application granted granted Critical
Publication of CN104470899B publication Critical patent/CN104470899B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380023358.XA 2012-03-09 2013-03-08 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 Active CN104470899B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261609022P 2012-03-09 2012-03-09
US61/609,022 2012-03-09
PCT/US2013/029912 WO2013134660A1 (en) 2012-03-09 2013-03-08 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
CN104470899A CN104470899A (zh) 2015-03-25
CN104470899B true CN104470899B (zh) 2017-12-26

Family

ID=48014301

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380023358.XA Active CN104470899B (zh) 2012-03-09 2013-03-08 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物

Country Status (10)

Country Link
US (1) US9409892B2 (cg-RX-API-DMAC7.html)
EP (1) EP2834220B1 (cg-RX-API-DMAC7.html)
JP (2) JP6129217B2 (cg-RX-API-DMAC7.html)
CN (1) CN104470899B (cg-RX-API-DMAC7.html)
AU (1) AU2013229922B2 (cg-RX-API-DMAC7.html)
CA (1) CA2866556C (cg-RX-API-DMAC7.html)
IL (1) IL234544A (cg-RX-API-DMAC7.html)
NZ (1) NZ700760A (cg-RX-API-DMAC7.html)
SG (1) SG11201405574UA (cg-RX-API-DMAC7.html)
WO (1) WO2013134660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SMT201800565T1 (it) 2012-07-16 2018-11-09 Fibrogen Inc Forme cristalline di un inibitore di prolil idrossilasi
RS60464B1 (sr) 2013-06-06 2020-07-31 Fibrogen Inc Farmaceutske formulacije inhibitora hif hidroksilaze
WO2015054579A1 (en) * 2013-10-11 2015-04-16 Isis Pharmaceuticals, Inc. Treatment of acute kidney injury with phd1 modulators
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
CN105367435A (zh) * 2015-12-03 2016-03-02 张伟 一种β-丙氨酸叔丁酯盐酸盐的制备方法
CN107188875B (zh) * 2016-03-15 2020-11-10 联化科技股份有限公司 一种取代苯酞类化合物的制备方法及其中间体
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
JP2019529522A (ja) 2016-10-10 2019-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子としての三環式スルホン類
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
EP3573615B1 (en) 2017-01-28 2024-06-12 Kingchem Life Science LLC A process for preparing 5-phenoxy-1(3h)isobenzofuranone
TW201920108A (zh) * 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
CN108084090B (zh) * 2017-12-20 2020-03-17 北京六合宁远科技有限公司 一种药物中间体含氮杂环的溴代化合物的合成方法
WO2021073623A1 (zh) * 2019-10-18 2021-04-22 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN113754569B (zh) * 2020-06-04 2024-07-02 四川国为制药有限公司 一种中间体化合物及其制备方法和用途
WO2023072246A1 (en) * 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
EP4447963A1 (en) * 2021-12-17 2024-10-23 Akebia Therapeutics Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
JP2025500888A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的ｐｈｄ１阻害剤としてのピコリンアミド化合物、組成物、及び使用方法
WO2023137422A1 (en) * 2022-01-13 2023-07-20 Fibrogen, Inc. Treatment for congestive heart failure
WO2024138317A1 (zh) * 2022-12-26 2024-07-04 中国科学院广州生物医药与健康研究院 一种甲状腺激素受体β激动剂化合物及其制备方法和应用
WO2024222881A1 (en) * 2023-04-28 2024-10-31 Insilico Medicine Ip Limited Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
WO2024222893A1 (en) * 2023-04-28 2024-10-31 Insilico Medicine Ip Limited Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
CN121100002A (zh) * 2023-04-28 2025-12-09 英矽智能科技知识产权有限公司 含脯氨酰羟化酶结构域的蛋白质(phd)抑制剂及其组合和用途
CN117486797A (zh) * 2023-11-23 2024-02-02 传健生物医药(厦门)有限公司 一种罗沙司他关键中间体及罗沙司他的制备方法
WO2025252553A1 (en) 2024-06-04 2025-12-11 Syngenta Crop Protection Ag Pesticidally-active 2,2-dihalocyclopropyl compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107144A (zh) * 1993-11-02 1995-08-23 赫彻斯特股份公司 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途
US7323475B2 (en) * 2003-06-06 2008-01-29 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and methods of use thereof
US7928120B2 (en) * 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
CA2272565A1 (en) 1996-11-27 1998-06-04 Du Pont Pharmaceuticals Company Integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
CA2450625A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
WO2002101073A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
ES2686625T3 (es) 2001-12-06 2018-10-18 Fibrogen, Inc. Métodos para el tratamiento o prevención de la anemia
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
ES2332798T3 (es) 2004-05-28 2010-02-12 Fibrogen, Inc. Ensayo de actividad de la prolil hidroxilasa de hif.
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
EP1919463B9 (en) 2005-06-15 2011-02-02 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
MX2009000286A (es) * 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
AU2009322393B2 (en) 2008-12-03 2017-02-02 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107144A (zh) * 1993-11-02 1995-08-23 赫彻斯特股份公司 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途
US7323475B2 (en) * 2003-06-06 2008-01-29 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and methods of use thereof
CN102718708A (zh) * 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US7928120B2 (en) * 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Approaches to the design of anti-fibrotic drugs;Trevor J. Franklin，等;《Biochemical Society Transactions》;19911231;第19卷;第812-815页 *

Also Published As

Publication number Publication date
HK1206743A1 (en) 2016-01-15
SG11201405574UA (en) 2014-10-30
JP2015509543A (ja) 2015-03-30
US9409892B2 (en) 2016-08-09
WO2013134660A1 (en) 2013-09-12
EP2834220A1 (en) 2015-02-11
CA2866556A1 (en) 2013-09-12
CN104470899A (zh) 2015-03-25
AU2013229922B2 (en) 2017-09-28
IL234544A (en) 2017-03-30
AU2013229922A1 (en) 2014-10-23
JP2017101089A (ja) 2017-06-08
NZ700760A (en) 2016-08-26
US20150038528A1 (en) 2015-02-05
JP6129217B2 (ja) 2017-05-17
CA2866556C (en) 2020-01-07
EP2834220B1 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
CN104470899B (zh) 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物
CN102264740B (zh) 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
CN103608346B (zh) 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
EP1866318B1 (en) Thienopyridine compounds, and methods of use thereof
CN102272117B (zh) 作为hif羟化酶抑制剂的苯并噻喃衍生物
JP4954200B2 (ja) ヒストン脱アセチル化酵素阻害剤
CN111094288B (zh) 具有mgat-2抑制活性的稠合环衍生物
CN101460497A (zh) 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
CN108697715A (zh) 包含帽依赖性核酸内切酶抑制剂及抗流感药的组合的流感治疗用药物
CN108929263A (zh) 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途
CN102702194A (zh) 抗病毒化合物
CN104244939A (zh) 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
CN106068265A (zh) 用于治疗代谢病症的二氢吡啶酮mgat2抑制剂
KR20090077975A (ko) Ｉｋｋ-베타 세린-트레오닌 단백질 키나아제 억제제
CN105263924B (zh) Cxcr7受体调节剂
WO2021063362A1 (zh) 磺基取代的联芳基类化合物或其盐及其制备方法和用途
WO2018145653A1 (zh) 联芳基类化合物及其制备方法和用途
US20140235673A1 (en) Pyridinedione carboxamide inhibitors of endothelial lipase
CN112679470B (zh) (e)-1-苯基4-烯基-1h-吡唑类化合物及其医药用途
HK1206743B (en) 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors
TW201620915A (zh) ３－氧代－四氫－呋喃並［３，２－ｂ］吡咯－４（５Ｈ）－基）衍生物之二
WO2022161416A1 (zh) 一种芳香化合物、其制备方法及应用
HK40088484A (zh) 抗病毒素1，3-二氧代茚化合物
WO2001083433A1 (en) Bifunctional inhibitors of malarial proteases and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200827

Address after: Room 101-601, unit 2, building 7, yard 88, Kechuang 6th Street, Daxing District, Beijing

Patentee after: FIBROGEN (CHINA) MEDICINE TECHNOLOGY DEVELOPMENT Co.,Ltd.

Address before: California, USA

Patentee before: FibroGen, Inc.